We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Evosep and Agilent Collaborate to Improve Proteomics Workflows

Evosep and Agilent Collaborate to Improve Proteomics Workflows content piece image
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

At the ASMS 2020 Reboot, Evosep and Agilent Technologies have announced their joint efforts to improve robust, high-throughput workflows for clinical research proteomics. The initial data from the collaboration was presented at the conference in poster ThP 489 as well as in an online webinar.

Mass spectrometry (MS)-based proteomics has become a central technology in biological research and it is now promising to become equally powerful for future clinical research, for instance through characterization of the plasma proteome and tissue proteomes in adequate depth. Proteomics as a technology may have lacked the speed and robustness necessary, but with recent advances in sample preparation and chromatography, accurate proteome quantitation in high throughput mode for thousands of samples is now possible.

Dr Nicolai Bache, Head of Application, Evosep elaborates: “The Evosep One separation solution fits perfectly with the routine focused applications developed by Agilent Technologies by enabling really high throughput sample separation for MS analyses while still being extremely easy to use for the customer. The combination of an Evosep One and an Agilent Technologies Mass Spectrometer, e.g. a triple Quadrupole, will enable ultra-robust, sensitive and fully automated workflows. What every lab would want and an important step forward for clinical research.”